Detalhe da pesquisa
1.
Pharmacogenetic variants and response to neoadjuvant single-agent doxorubicin or docetaxel: a study in locally advanced breast cancer patients participating in the NCT00123929 phase 2 randomized trial.
Pharmacogenet Genomics
; 28(11): 245-250, 2018 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-30334909
2.
Exome array analysis identifies ETFB as a novel susceptibility gene for anthracycline-induced cardiotoxicity in cancer patients.
Breast Cancer Res Treat
; 167(1): 249-256, 2018 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-28913729
3.
Exome array analysis identifies GPR35 as a novel susceptibility gene for anthracycline-induced cardiotoxicity in childhood cancer.
Pharmacogenet Genomics
; 27(12): 445-453, 2017 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-28961156
4.
Intermediate molecular phenotypes to identify genetic markers of anthracycline-induced cardiotoxicity risk.
bioRxiv
; 2023 Jan 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-36712139
5.
Intermediate Molecular Phenotypes to Identify Genetic Markers of Anthracycline-Induced Cardiotoxicity Risk.
Cells
; 12(15)2023 07 27.
Artigo
em Inglês
| MEDLINE | ID: mdl-37566035
6.
Regulatory CDH4 Genetic Variants Associate With Risk to Develop Capecitabine-Induced Hand-Foot Syndrome.
Clin Pharmacol Ther
; 109(2): 462-470, 2021 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-32757270
7.
Human genetics: international projects and personalized medicine.
Drug Metab Pers Ther
; 31(1): 3-8, 2016 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-26581075